NASDAQ: EQ - Equillium, Inc.

六个月盈利: -51.27%
股息率: 0.00%
部门: Healthcare

促销时间表 Equillium, Inc.

先进的时间表 简单图表
Financial Markets by TradingView

关于公司 Equillium, Inc.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis.

更多详情
It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California.
添加到比较列表
添加到观察列表
添加到投资组合
添加价格通知

IPO date 2018-10-11
ISIN US29446K1060
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://equilliumbio.com
Цена ао 0.758
每日价格变化: -16.93% (0.488)
每周价格变化: -47.55% (0.773)
每月价格变化: -47.01% (0.765)
3个月内价格变化: -41.59% (0.694)
六个月内的价格变化: -51.27% (0.832)
每年价格变化: -82.45% (2.31)
3年内价格变化: -87.68% (3.29)
5年内价格变化: -92.05% (5.1)
年初以来价格变化: -45.22% (0.74)
所有参数

低估

姓名 意义 年级
P/S 0.6101 10
P/BV 0.9753 9
P/E 0 0
EV/EBITDA 0.0261 10
全部的: 6.13

效率

姓名 意义 年级
ROA, % -26.39 0
ROE, % -59.08 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -0.0572 10
全部的: 9.4

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 128.97 10
盈利能力 Ebitda, % -54.54 0
盈利能力 EPS, % -73.88 0
全部的: 2
更多详情

机构 体积 分享, %
Decheng Capital Management III (Cayman), LLC 4447308 12.61
Decheng Capital LLC 4447308 12.61
Vanguard Group Inc 836930 2.37
Cota Capital Management, LLC 562278 1.59
Tang Capital Management, LLC 400000 1.13
JP Morgan Chase & Company 350031 0.99
Renaissance Technologies, LLC 347500 0.99
Geode Capital Management, LLC 172387 0.49
Commonwealth Equity Services, LLC 100000 0.28
Callan Capital LLC 99688 0.28

ETF分享, %本年盈利能力, %股息, %
iShares Micro-Cap ETF 0.0032 17.09 1.54048
017.091.54



导师 职称 支付 出生年份
Mr. Daniel Mark Bradbury Executive Chairman 158k 1961 (64 年)
Mr. Bruce D. Steel C.F.A. Co-Founder, President, CEO & Director 779.87k 1966 (59 年)
Ms. Christine Zedelmayer M.B.A., P.M.P. Senior VP & COO 553.73k 1970 (55 年)
Dr. Stephen Connelly Ph.D. Chief Scientific Officer & Director 571.32k 1982 (43 年)
Mr. Jason A. Keyes Chief Financial Officer N/A 1971 (54 年)
Mr. Michael Moore Vice President of Investor Relations & Corporate Communications N/A
Dr. Matthew Ritter Ph.D. Senior Vice President of Corporate Development N/A
Mr. Joel M. Rothman Chief Development Officer N/A 1969 (56 年)
Penny Tom Senior VP of Finance & Principal Accounting Officer N/A

地址: United States, La Jolla. CA, 2223 Avenida De La Playa - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://equilliumbio.com